Real-world experience with CLAIRYG® 50 mg/mL (intravenous immunoglobulin) in children under 12 years with primary immunodeficiency or immmune thrombocytopenia: a post-approval safety study.

Date publication

octobre 2023

Journal

Frontiers in pediatrics

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FOUYSSAC Fanny

Tous les auteurs :
Mahlaoui N, Fouyssac F, Mazingue F, Mallebranche C, Barthez-Toullec M, Denti L, Ruhier K, André-Bonnet MH, Marie-Cardine A, Aladjidi N, Stephan JL

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37849499

Résumé

This study presents the results of a real-life, multicenter, prospective, post-approval safety evaluation of Clairyg® 50 mg/mL, a 5% intravenous immunoglobulin (IVIg) liquid, in 59 children (aged < 12 years) with primary immunodeficiency diseases (PID) ( = 32) or immune thrombocytopenia (ITP) ( = 27) in France.

Mots clés

Clairyg®, immune thrombocytopenia, immunoglobulin, pediatrics, post-approval safety study, primary immunodeficiency, real-world experience

Référence

Front Pediatr. 2023 10 2;11:1260296